Expression of FANCG gene in acute myeloid leukemia.
10.7534/j.issn.1009-2137.2013.01.002
- Author:
Xian-Liang DUAN
1
;
Qin-Ling WANG
;
Jin-Gang WANG
;
Chang-Yu WANG
;
Hua FAN
Author Information
1. Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Fanconi Anemia Complementation Group G Protein;
genetics;
Female;
Humans;
Leukemia, Myeloid, Acute;
genetics;
pathology;
Male;
Middle Aged;
Prognosis;
RNA, Messenger;
genetics;
Real-Time Polymerase Chain Reaction
- From:
Journal of Experimental Hematology
2013;21(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the relationship between expression of the FANCG gene and adult sporadic acute myeloid leukemia (AML), real-time PCR with SYBR Green I technique was used for detecting FANCG gene expression level in bone marrow mononuclear cells of 54 newly diagnosed AML patients, 46 AML patients in complete remission (CR) and 36 control samples. β-actin gene was used as internal reference. Relative changes of FANCG gene expression level were detected by 2(-ΔΔCT) method in newly diagnosed AML patients and control samples, in newly diagnosed AML and patient in CR, as well as in AML patients in CR and control samples. The results showed that the relative expression level of FANCG mRNA was 0.56 ± 0.27 in newly diagnosed group, 0.75 ± 0.54 in AML CR group, and 0.85 ± 0.45 in control group. The expression level of FANCG mRNA in newly diagnosed group was significantly lower than that in control and AML CR groups (P < 0.05). There was no statistically significant deference in comparison of AML CR group with the control group (P > 0.05). It is concluded that the expression of FANCG gene decrease in the newly diagnosed AML patients. There is no significant difference between AML CR group and control group, which indicated that FANCG gene may be related with the onset and the prognosis of AML, and may provide a clinical value for evaluating effect of chemotherapy.
